Safety and efficacy data from Phase III trial of BNT162b2 vaccine published
Pfizer and BioNTech's data on BNT162b2, their COVID-19 vaccine, has…
Pfizer and BioNTech's data on BNT162b2, their COVID-19 vaccine, has been published in a new scientific paper, demonstrating its 95 percent efficacy rate.